胰腺癌：转移性疾病的治疗试验。
Pancreas cancer: Therapeutic trials in metastatic disease.
机构信息
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
出版信息
J Surg Oncol. 2021 May;123(6):1475-1488. doi: 10.1002/jso.26359.
Abstract
Metastatic pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer-related mortality in 2021. Cytotoxic therapies are the therapeutic mainstay for PDAC. The recent approval of olaparib as maintenance therapy for germline BRCA1/2-mutated PDAC and pembrolizumab for mismatch repair deficient PDAC represent molecularly targeted approaches for this disease. Investigational therapeutic strategies include targeting the stroma, metabolism, tumor microenvironment, and the immune system, and selected approaches are reviewed herein.
摘要
转移性胰腺导管腺癌 (PDAC) 是 2021 年癌症相关死亡的主要原因。细胞毒性疗法是 PDAC 的主要治疗方法。奥拉帕利作为种系 BRCA1/2 突变 PDAC 的维持治疗以及帕博利珠单抗作为错配修复缺陷 PDAC 的治疗药物的最近获批代表了该疾病的分子靶向治疗方法。研究性治疗策略包括针对基质、代谢、肿瘤微环境和免疫系统，本文回顾了一些选定的方法。
相似文献
1
Pancreas cancer: Therapeutic trials in metastatic disease.
J Surg Oncol. 2021 May;123(6):1475-1488. doi: 10.1002/jso.26359.
2
New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma.
Drugs. 2020 May;80(7):647-669. doi: 10.1007/s40265-020-01304-0.
3
The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.
Expert Rev Anticancer Ther. 2018 Feb;18(2):131-148. doi: 10.1080/14737140.2018.1417844. Epub 2017 Dec 19.
4
Perspectives in the treatment of pancreatic adenocarcinoma.
World J Gastroenterol. 2015 Aug 21;21(31):9297-316. doi: 10.3748/wjg.v21.i31.9297.
5
Emerging Treatment Strategies in Pancreatic Cancer.
Pancreas. 2021 Jul 1;50(6):773-787. doi: 10.1097/MPA.0000000000001845.
6
Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.
Biochim Biophys Acta Rev Cancer. 2020 Aug;1874(1):188387. doi: 10.1016/j.bbcan.2020.188387. Epub 2020 Jun 21.
7
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
J Hematol Oncol. 2020 Oct 2;13(1):130. doi: 10.1186/s13045-020-00958-3.
8
Novel Therapeutics for Pancreatic Adenocarcinoma.
Hematol Oncol Clin North Am. 2015 Aug;29(4):777-87. doi: 10.1016/j.hoc.2015.04.006.
9
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.
Int J Mol Sci. 2017 Jun 22;18(7):1338. doi: 10.3390/ijms18071338.
10
Multimodal treatment of resectable pancreatic ductal adenocarcinoma.
Crit Rev Oncol Hematol. 2017 Mar;111:152-165. doi: 10.1016/j.critrevonc.2017.01.015. Epub 2017 Feb 4.
引用本文的文献
1
Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear.
Ther Adv Med Oncol. 2024 Apr 4;16:17588359241234487. doi: 10.1177/17588359241234487. eCollection 2024.
2
The protein phosphatase-2A subunit PR130 is involved in the formation of cytotoxic protein aggregates in pancreatic ductal adenocarcinoma cells.
Cell Commun Signal. 2024 Apr 3;22(1):217. doi: 10.1186/s12964-024-01597-8.
3
Clinical and Preclinical Targeting of Oncogenic Pathways in PDAC: Targeted Therapeutic Approaches for the Deadliest Cancer.
Int J Mol Sci. 2024 Mar 1;25(5):2860. doi: 10.3390/ijms25052860.
4
Perioperative oncolytic virotherapy to counteract surgery-induced immunosuppression and improve outcomes in pancreatic ductal adenocarcinoma.
Front Oncol. 2023 Feb 16;13:1071751. doi: 10.3389/fonc.2023.1071751. eCollection 2023.
5
Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype.
JCI Insight. 2022 May 23;7(10):e151353. doi: 10.1172/jci.insight.151353.
6
Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma.
Front Med (Lausanne). 2021 Nov 19;8:720128. doi: 10.3389/fmed.2021.720128. eCollection 2021.
7
Rationale for MYC imaging and targeting in pancreatic cancer.
EJNMMI Res. 2021 Oct 12;11(1):104. doi: 10.1186/s13550-021-00843-1.
8
[F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma.
EJNMMI Res. 2021 Jul 28;11(1):70. doi: 10.1186/s13550-021-00808-4.
9
Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions.
Cancers (Basel). 2021 Jun 22;13(13):3119. doi: 10.3390/cancers13133119.
本文引用的文献
1
Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program.
JCO Precis Oncol. 2019 Dec;3:1-10. doi: 10.1200/PO.19.00115.
2
KRAS Inhibition with Sotorasib in Advanced Solid Tumors.
N Engl J Med. 2020 Sep 24;383(13):1207-1217. doi: 10.1056/NEJMoa1917239. Epub 2020 Sep 20.
3
Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients.
Oncoimmunology. 2020 Jun 10;9(1):1773201. doi: 10.1080/2162402X.2020.1773201.
4
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Lancet Oncol. 2020 Oct;21(10):1353-1365. doi: 10.1016/S1470-2045(20)30445-9. Epub 2020 Sep 10.
5
DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives.
Gut. 2021 Mar;70(3):606-617. doi: 10.1136/gutjnl-2019-319984. Epub 2020 Aug 27.
6
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.
Cancer Discov. 2021 Jan;11(1):142-157. doi: 10.1158/2159-8290.CD-20-0142. Epub 2020 Aug 19.
7
Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.
Cell. 2020 Aug 20;182(4):1044-1061.e18. doi: 10.1016/j.cell.2020.07.009. Epub 2020 Aug 13.
8
Metastatic Pancreatic Cancer: ASCO Guideline Update.
J Clin Oncol. 2020 Sep 20;38(27):3217-3230. doi: 10.1200/JCO.20.01364. Epub 2020 Aug 5.
9
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma.
J Clin Oncol. 2020 Sep 20;38(27):3185-3194. doi: 10.1200/JCO.20.00590. Epub 2020 Jul 24.
10
Mismatch Repair Pathway, Genome Stability and Cancer.
Front Mol Biosci. 2020 Jun 26;7:122. doi: 10.3389/fmolb.2020.00122. eCollection 2020.
Zotero 插件